Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Human iPSC-Derived Down Syndrome Astrocytes Display Genome-Wide Perturbations in Gene Expression, an Altered Adhesion Profile, and Increased Cellular Dynamics.

Bally BP, Farmer WT, Jones EV, Jessa S, Kacerovsky JB, Mayran A, Peng H, Lefebvre JL, Drouin J, Hayer A, Ernst C, Murai KK.

Hum Mol Genet. 2020 Jan 15. pii: ddaa003. doi: 10.1093/hmg/ddaa003. [Epub ahead of print]

PMID:
31943018
2.

Fifteen-year history of the European head and neck society.

Hoşal Ş, Golusiński W, Andry G, Leemans CR, LeFebvre JL.

Oral Oncol. 2019 Oct;97:112-114. doi: 10.1016/j.oraloncology.2019.08.022. Epub 2019 Sep 3. No abstract available.

PMID:
31491674
3.

Laryngeal Preservation Strategies in Locally Advanced Laryngeal and Hypopharyngeal Cancers.

Argiris A, Lefebvre JL.

Front Oncol. 2019 May 31;9:419. doi: 10.3389/fonc.2019.00419. eCollection 2019. Review.

4.

Prevalence and characteristics of HPV-driven oropharyngeal cancer in France.

Mirghani H, Bellera C, Delaye J, Dolivet G, Fakhry N, Bozec A, Garrel R, Malard O, Jegoux F, Maingon P, Sarini J, Noel G, Duflo S, Temam S, Lefebvre JL, Costes-Martineau V.

Cancer Epidemiol. 2019 Aug;61:89-94. doi: 10.1016/j.canep.2019.05.007. Epub 2019 May 31.

PMID:
31158796
5.

Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions.

Haddad RI, Posner M, Hitt R, Cohen EEW, Schulten J, Lefebvre JL, Vermorken JB.

Ann Oncol. 2018 May 1;29(5):1130-1140. doi: 10.1093/annonc/mdy102.

6.

Combinatorial Effects of Alpha- and Gamma-Protocadherins on Neuronal Survival and Dendritic Self-Avoidance.

Ing-Esteves S, Kostadinov D, Marocha J, Sing AD, Joseph KS, Laboulaye MA, Sanes JR, Lefebvre JL.

J Neurosci. 2018 Mar 14;38(11):2713-2729. doi: 10.1523/JNEUROSCI.3035-17.2018. Epub 2018 Feb 8.

7.

Neuronal territory formation by the atypical cadherins and clustered protocadherins.

Lefebvre JL.

Semin Cell Dev Biol. 2017 Sep;69:111-121. doi: 10.1016/j.semcdb.2017.07.040. Epub 2017 Jul 27. Review.

PMID:
28756270
8.

Long-term update of the 24954 EORTC phase III trial on larynx preservation.

Henriques De Figueiredo B, Fortpied C, Menis J, Lefebvre JL, Barzan L, de Raucourt D, Geoffrois L, Giurgea L, Hupperets P, Leemans CR, Licitra L, Rolland F, Tesselaar M, Vermorken JB, Grégoire V; EORTC Head and Neck Cancer and Radiation Oncology Cooperative Groups.

Eur J Cancer. 2016 Sep;65:109-12. doi: 10.1016/j.ejca.2016.06.024. Epub 2016 Aug 2.

PMID:
27494036
9.

Development of dendritic form and function.

Lefebvre JL, Sanes JR, Kay JN.

Annu Rev Cell Dev Biol. 2015;31:741-77. doi: 10.1146/annurev-cellbio-100913-013020. Epub 2015 Sep 29. Review.

PMID:
26422333
10.

[Papillomavirus and cancers: plea for extending the vaccination to boys].

Abramowitz L, Descamps P, Denis F, Dommergues MA, Lacau St Guily J, Lefebvre JL, Masse G, Judlin P.

Bull Cancer. 2014 Jul-Aug;101(7-8):657-62. doi: 10.1684/bdc.2014.2013. French. No abstract available.

PMID:
25091647
11.

Determinants of patient delay in doctor consultation in head and neck cancers (Protocol DEREDIA).

Christophe V, Leroy T, Seillier M, Duthilleul C, Julieron M, Clisant S, Foncel J, Vallet F, Lefebvre JL.

BMJ Open. 2014 Jul 25;4(7):e005286. doi: 10.1136/bmjopen-2014-005286.

12.

[Squamous cell carcinoma of the hypopharynx and larynx: evidence-based care].

Fayette J, Pointreau Y, Bourhis J, Lefebvre JL.

Bull Cancer. 2014 May 1;101(5):438-44. doi: 10.1684/bdc.2014.1945. Review. French.

PMID:
24886894
13.

Best practices in the management of the psycho-oncologic aspects of head and neck cancer patients: recommendations from the European Head and Neck Cancer Society Make Sense Campaign.

Reich M, Leemans CR, Vermorken JB, Bernier J, Licitra L, Parmar S, Golusinski W, Lefebvre JL.

Ann Oncol. 2014 Nov;25(11):2115-24. doi: 10.1093/annonc/mdu105. Epub 2014 Mar 7.

14.

Dendrite self-avoidance requires cell-autonomous slit/robo signaling in cerebellar purkinje cells.

Gibson DA, Tymanskyj S, Yuan RC, Leung HC, Lefebvre JL, Sanes JR, Chédotal A, Ma L.

Neuron. 2014 Mar 5;81(5):1040-1056. doi: 10.1016/j.neuron.2014.01.009.

15.

An international phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on behalf of the EORTC Head and Neck and the EORTC Radiation Oncology Group.

Bottomley A, Tridello G, Coens C, Rolland F, Tesselaar ME, Leemans CR, Hupperets P, Licitra L, Vermorken JB, Van Den Weyngaert D, Truc G, Barillot I, Lefebvre JL.

Cancer. 2014 Feb 1;120(3):390-8. doi: 10.1002/cncr.28392. Epub 2013 Oct 25.

16.

Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer.

Lartigau EF, Tresch E, Thariat J, Graff P, Coche-Dequeant B, Benezery K, Schiappacasse L, Degardin M, Bondiau PY, Peiffert D, Lefebvre JL, Lacornerie T, Kramar A.

Radiother Oncol. 2013 Nov;109(2):281-5. doi: 10.1016/j.radonc.2013.08.012. Epub 2013 Nov 18.

PMID:
24262821
17.

A systematic review of current and emerging approaches in the field of larynx preservation.

Denaro N, Russi EG, Lefebvre JL, Merlano MC.

Radiother Oncol. 2014 Jan;110(1):16-24. doi: 10.1016/j.radonc.2013.08.016. Epub 2013 Oct 15. Review.

PMID:
24139733
18.

[Advances in head and neck cancers on behalf of the French Intergroup ORL and GORTEC].

Thariat J, Jegoux F, Pointreau Y, Fayette J, Boisselier P, Blanchard P, Alfonsi M, Aupérin A, Bardet E, Bensadoun RJ, Garaud P, Geoffrois L, Graff P, Guigay J, Janot F, Lapeyre M, Lefebvre JL, Martin L, Racadot S, Rolland F, Sire C, Tao Y, Tuchais C, Chibaudel B, Girard-Calais MH, Cornely A, Vintonenko N, Calais G, De Raucourt D, Lacau Saint-Guily J, Bourhis J.

Bull Cancer. 2013 Oct;100(10):983-97. doi: 10.1684/bdc.2013.1829. Review. French.

PMID:
24126183
19.

Quality assurance in head and neck surgical oncology: EORTC 24954 trial on larynx preservation.

Leemans CR, Tijink BM, Langendijk JA, Andry G, Hamoir M, Lefebvre JL; Subcommittee of Surgery of the EORTC Head and Neck Cooperative Group.

Eur J Surg Oncol. 2013 Sep;39(9):1013-8. doi: 10.1016/j.ejso.2013.06.007. Epub 2013 Jun 28.

PMID:
23810332
20.

Sinonasal cancer: Analysis of oncological failures in 156 consecutive cases.

Mirghani H, Mortuaire G, Armas GL, Hartl D, Aupérin A, El Bedoui S, Chevalier D, Lefebvre JL.

Head Neck. 2014 May;36(5):667-74. doi: 10.1002/hed.23356. Epub 2013 Jul 30.

PMID:
23606521
21.

Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study.

Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, de Raucourt D, Malard O, Degardin M, Tuchais C, Blot E, Rives M, Reyt E, Tourani JM, Geoffrois L, Peyrade F, Guichard F, Chevalier D, Babin E, Lang P, Janot F, Calais G, Garaud P, Bardet E.

J Clin Oncol. 2013 Mar 1;31(7):853-9. doi: 10.1200/JCO.2012.42.3988. Epub 2013 Jan 22. Erratum in: J Clin Oncol. 2013 May 1;31(13):1702.

PMID:
23341517
22.

Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Chan AT, Grégoire V, Lefebvre JL, Licitra L, Hui EP, Leung SF, Felip E; EHNS–ESMO–ESTRO Guidelines Working Group.

Ann Oncol. 2012 Oct;23 Suppl 7:vii83-5. No abstract available.

PMID:
22997460
23.

Nodal recurrence of sinonasal cancer: does the risk of cervical relapse justify a prophylactic neck treatment?

Mirghani H, Hartl D, Mortuaire G, Armas GL, Aupérin A, Chevalier D, Lefebvre JL.

Oral Oncol. 2013 Apr;49(4):374-80. doi: 10.1016/j.oraloncology.2012.10.002. Epub 2012 Oct 30.

PMID:
23116962
24.

Morphologic assessment of mandibular reconstruction by free fibula flap and donor-site functional impairment in a series of 23 patients.

Bartaire E, Mouawad F, Mallet Y, Milet P, El Bedoui S, Ton Van J, Chevalier D, Lefebvre JL.

Eur Ann Otorhinolaryngol Head Neck Dis. 2012 Oct;129(5):230-7. doi: 10.1016/j.anorl.2011.06.004. Epub 2012 Oct 15.

25.

Functional significance of isoform diversification in the protocadherin gamma gene cluster.

Chen WV, Alvarez FJ, Lefebvre JL, Friedman B, Nwakeze C, Geiman E, Smith C, Thu CA, Tapia JC, Tasic B, Sanes JR, Maniatis T.

Neuron. 2012 Aug 9;75(3):402-9. doi: 10.1016/j.neuron.2012.06.039. Erratum in: Neuron. 2012 Sep 6;75(5):928-9.

26.

Protocadherins mediate dendritic self-avoidance in the mammalian nervous system.

Lefebvre JL, Kostadinov D, Chen WV, Maniatis T, Sanes JR.

Nature. 2012 Aug 23;488(7412):517-21. doi: 10.1038/nature11305.

27.

Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891.

Lefebvre JL, Andry G, Chevalier D, Luboinski B, Collette L, Traissac L, de Raucourt D, Langendijk JA; EORTC Head and Neck Cancer Group.

Ann Oncol. 2012 Oct;23(10):2708-14. Epub 2012 Apr 6.

28.

Larynx preservation.

Lefebvre JL.

Curr Opin Oncol. 2012 May;24(3):218-22. doi: 10.1097/CCO.0b013e3283523c95. Review.

PMID:
22450148
29.

Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study.

Comet B, Kramar A, Faivre-Pierret M, Dewas S, Coche-Dequeant B, Degardin M, Lefebvre JL, Lacornerie T, Lartigau EF.

Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):203-9. doi: 10.1016/j.ijrobp.2011.11.054. Epub 2012 Feb 11.

PMID:
22331006
30.

Functional and sensitive outcomes after tongue reconstruction: about a series of 30 patients.

Guerin-Lebailly C, Mallet Y, Lambour V, Fournier C, El Bedoui S, Ton Van J, Lefebvre JL.

Oral Oncol. 2012 Mar;48(3):272-7. doi: 10.1016/j.oraloncology.2011.10.010. Epub 2011 Dec 1.

PMID:
22137578
31.

The impact of a total laryngectomy on the patients' quality of life.

Lefebvre JL.

Eur Arch Otorhinolaryngol. 2011 Oct;268(10):1397-8. doi: 10.1007/s00405-011-1662-3. No abstract available.

PMID:
21720850
32.

Larynx preservation: what is the standard treatment?

Horn S, Ozsahin M, Lefèbvre JL, Horiot JC, Lartigau E; Association of Radiotherapy and Oncology of the Mediterranean Area (AROME).

Crit Rev Oncol Hematol. 2012 Dec;84 Suppl 1:e97-e105. doi: 10.1016/j.critrevonc.2010.11.008. Epub 2010 Dec 23. Review.

PMID:
21185198
33.

Induction chemotherapy in head and neck cancer: a new paradigm.

Pointreau Y, Atean I, Fayette J, Calais G, Lefebvre JL.

Anticancer Drugs. 2011 Aug;22(7):613-20. doi: 10.1097/CAD.0b013e3283425871. Review.

PMID:
21160420
34.

Candidates for larynx preservation: the next step?

Lefebvre JL.

Oncologist. 2010;15 Suppl 3:30-2. doi: 10.1634/theoncologist.2010-S3-30. Review.

35.

Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Chan AT, Grégoire V, Lefebvre JL, Licitra L, Felip E; EHNS-ESMO-ESTRO Guidelines Working Group.

Ann Oncol. 2010 May;21 Suppl 5:v187-9. doi: 10.1093/annonc/mdq186. No abstract available.

36.

Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Grégoire V, Lefebvre JL, Licitra L, Felip E; EHNS-ESMO-ESTRO Guidelines Working Group.

Ann Oncol. 2010 May;21 Suppl 5:v184-6. doi: 10.1093/annonc/mdq185. No abstract available.

37.

Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?

Bourhis J, Lefebvre JL, Vermorken JB.

Eur J Cancer. 2010 Jul;46(11):1979-89. doi: 10.1016/j.ejca.2010.05.015. Epub 2010 Jun 17. Review.

PMID:
20561781
38.

Surgery for Laryngopharyngeal SCC in the Era of Organ Preservation.

Lefebvre JL.

Clin Exp Otorhinolaryngol. 2009 Dec;2(4):159-63. doi: 10.3342/ceo.2009.2.4.159. Epub 2009 Dec 31.

39.

Head and neck cancer surgery in the elderly--does age influence the postoperative course?

Milet PR, Mallet Y, El Bedoui S, Penel N, Servent V, Lefebvre JL.

Oral Oncol. 2010 Feb;46(2):92-5. doi: 10.1016/j.oraloncology.2009.10.002. Epub 2009 Dec 29.

PMID:
20036609
40.

The free vascularized flap and the pectoralis major pedicled flap options: comparative results of reconstruction of the tongue.

Mallet Y, El Bedoui S, Penel N, Ton Van J, Fournier C, Lefebvre JL.

Oral Oncol. 2009 Dec;45(12):1028-31. doi: 10.1016/j.oraloncology.2009.05.639. Epub 2009 Sep 30.

PMID:
19796982
41.

[Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy].

Bardet E, Bourhis J, Cals L, Fayette J, Guigay J, Hans S, Saint-Guily JL, Lagarde F, Lallemant B, Milano G, Rolland F, Lefebvre JL.

Bull Cancer. 2009 Oct;96(10):1013-28. doi: 10.1684/bdc.2009.0951. French.

42.

"Sufficient life expectancy": an amazing inclusion criterion in cancer phase II-III trials.

Penel N, Clisant S, Lefebvre JL, Adenis A.

J Clin Oncol. 2009 Sep 10;27(26):e105. doi: 10.1200/JCO.2009.24.1810. Epub 2009 Aug 10. No abstract available.

PMID:
19667257
43.

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.

Thomas F, Rochaix P, White-Koning M, Hennebelle I, Sarini J, Benlyazid A, Malard L, Lefebvre JL, Chatelut E, Delord JP.

Eur J Cancer. 2009 Sep;45(13):2316-23. doi: 10.1016/j.ejca.2009.05.007. Epub 2009 Jun 10.

PMID:
19523815
44.

Major advances in the knowledge and understanding of the epidemiology, aetiopathogenesis, diagnosis, management and prognosis of oral cancer.

Rapidis AD, Gullane P, Langdon JD, Lefebvre JL, Scully C, Shah JP.

Oral Oncol. 2009 Apr-May;45(4-5):299-300. doi: 10.1016/j.oraloncology.2009.04.001. No abstract available.

PMID:
19411038
45.

Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary.

Lefebvre JL, Ang KK; Larynx Preservation Consensus Panel.

Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1293-303. doi: 10.1016/j.ijrobp.2008.10.047.

PMID:
19306746
46.

Wnt signals organize synaptic prepattern and axon guidance through the zebrafish unplugged/MuSK receptor.

Jing L, Lefebvre JL, Gordon LR, Granato M.

Neuron. 2009 Mar 12;61(5):721-33. doi: 10.1016/j.neuron.2008.12.025.

47.

Larynx preservation clinical trial design: key issues and recommendations--a consensus panel summary.

Lefebvre JL, Ang KK; Larynx Preservation Consensus Panel.

Head Neck. 2009 Apr;31(4):429-41. doi: 10.1002/hed.21081.

PMID:
19283793
48.

Docetaxel in the treatment of squamous cell carcinoma of the head and neck.

Rapidis A, Sarlis N, Lefebvre JL, Kies M.

Ther Clin Risk Manag. 2008 Oct;4(5):865-86. Erratum in: Ther Clin Risk Manag. 2008 Dec;4(6):1381.

49.

Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy.

Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L, Hupperets P, Barzan L, de Raucourt D, Chevalier D, Licitra L, Lunghi F, Stupp R, Lacombe D, Bogaerts J, Horiot JC, Bernier J, Vermorken JB; EORTC Head and Neck Cancer Cooperative Group; EORTC Radiation Oncology Group.

J Natl Cancer Inst. 2009 Feb 4;101(3):142-52. doi: 10.1093/jnci/djn460. Epub 2009 Jan 27.

50.

[Information on head, neck and lung cancers].

Dansin E, Lefebvre JL.

Bull Cancer. 2009;96 Suppl 1:S5-11. doi: 10.1684/bdc.2008.0784. Review. French.

PMID:
19433369

Supplemental Content

Loading ...
Support Center